Among nonhospitalized patients with mild to moderate COVID-19 and at risk of disease progression, a single intravenous dose of sotrovimab, compared with placebo, significantly reduced the risk of a composite end point of all-cause hospitalization or death through day 29.

The findings support sotrovimab as a treatment option for nonhospitalized, high-risk patients with mild to moderate COVID-19, although efficacy against SARS-CoV-2 variants that have emerged since the study was completed is unknown.

Enrollment was stopped early for efficacy at the prespecified interim analysis.

Among 1,057 patients randomized, the median duration of follow-up was 103 days for sotrovimab and 102 days for placebo.

All-cause hospitalization lasting longer than 24 hours or death was significantly reduced with sotrovimab.

Read More